Compare BHK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | ALT |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.4M | 573.8M |
| IPO Year | N/A | 2005 |
| Metric | BHK | ALT |
|---|---|---|
| Price | $8.96 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 275.4K | ★ 5.3M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.65 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $8.69 | $2.56 |
| 52 Week High | $10.12 | $6.44 |
| Indicator | BHK | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 56.56 |
| Support Level | $8.85 | $2.80 |
| Resistance Level | $9.05 | $3.32 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 27.78 | 70.00 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.